scholarly journals Circulating Tumor Cells Expressing the Prostate Specific Membrane Antigen (PSMA) Indicate Worse Outcome in Primary, Non-Metastatic Triple-Negative Breast Cancer

2020 ◽  
Vol 10 ◽  
Author(s):  
Sabine Kasimir-Bauer ◽  
Corinna Keup ◽  
Oliver Hoffmann ◽  
Siegfried Hauch ◽  
Rainer Kimmig ◽  
...  
2020 ◽  
Vol 9 (2) ◽  
pp. 353 ◽  
Author(s):  
Manuel Abreu ◽  
Pablo Cabezas-Sainz ◽  
Thais Pereira-Veiga ◽  
Catalina Falo ◽  
Alicia Abalo ◽  
...  

Traditionally, studies to address the characterization of mechanisms promoting tumor aggressiveness and progression have been focused only on primary tumor analyses, which could provide relevant information but have limitations to really characterize the more aggressive tumor population. To overcome these limitations, circulating tumor cells (CTCs) represent a noninvasive and valuable tool for real-time profiling of disseminated tumor cells. Therefore, the aim of the present study was to explore the value of CTC enumeration and characterization to identify markers associated with the outcome and the aggressiveness of triple-negative breast cancer (TNBC). For that aim, the CTC population from 32 patients diagnosed with TNBC was isolated and characterized. This population showed important cell plasticity in terms of expression of epithelia/mesenchymal and stemness markers, suggesting the relevance of epithelial to mesenchymal transition (EMT) intermediate phenotypes for efficient tumor dissemination. Importantly, the CTC signature demonstrated prognostic value to predict the patients’ outcome and pointed to a relevant role of tissue inhibitor of metalloproteinases 1 (TIMP1) and androgen receptor (AR) for TNBC biology. Furthermore, we also analyzed the usefulness of the AR and TIMP1 blockade to target TNBC proliferation and dissemination using in vitro and in vivo zebra fish and mouse models. Overall, the molecular characterization of CTCs from advanced TNBC patients identifies highly specific biomarkers with potential applicability as noninvasive prognostic markers and reinforced the value of TIMP1 and AR as potential therapeutic targets to tackle the most aggressive breast cancer.


Oncotarget ◽  
2016 ◽  
Vol 8 (3) ◽  
pp. 5309-5322 ◽  
Author(s):  
Sofia Agelaki ◽  
Melina Dragolia ◽  
Harris Markonanolaki ◽  
Saad Alkahtani ◽  
Christos Stournaras ◽  
...  

2014 ◽  
Vol 157 (1) ◽  
pp. 159-161 ◽  
Author(s):  
A. V. Lavrov ◽  
Zh. I. Zubtsova ◽  
D. A. Zubtsov ◽  
M. A. Frolova ◽  
E. O. Ignatova ◽  
...  

2021 ◽  
Vol 6 (4) ◽  
pp. 373-377
Author(s):  
Henry L Gomez ◽  
Carlos A. Castaneda ◽  
Miluska Castillo ◽  
James Reuben ◽  
Hui Gao ◽  
...  

Objective: Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) provide tumor information in breast cancer. Our objective was to characterize CTCs, and contrasted them with ctDNA PIK3CA mutation in 24 triple-negative breast cancer (TNBC). Methods: CTCs genes were characterized by AdnaTest protocol and ctDNA by digital PCR. Results:  We found CTCs genes in 37.5% and ctDNA PIK3CA mutations in 29.16%. Three cases with CTCs genes had concurrent ctDNA PIK3CA mutations. MUC1 or GA733-2 were found in 4 cases, and 3 of them had concurrent ctDNA PIK3CA. CTCs ALDH1/TWIST1 were found in 2 cases, AKT2 in one and PI3Kα in another, and none had concurrent ctDNA PIK3CA mutations. There was no correlation between CTCs and ctDNA detection. All 3 cases with CTC & cDNA concurrent finding underwent death during follow-up. Conclusion: Infrequent concurrent detection of CTC and ctDNA presence suggests that both represent independent processes in TNBC patients, and could identify worst prognosis cases.


Sign in / Sign up

Export Citation Format

Share Document